» Articles » PMID: 38314402

Dynamic Tracking of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) Following Intravenous Administration in Mice Model

Abstract

Introduction: In the past decades, human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have sparked interest in cellular therapy due to their immunomodulatory properties. Nevertheless, the fate of hUC-MSCs in the body remains poorly understood. This study aimed to investigate the biodistribution, homing and clearance of systemically administered hUC-MSCs in healthy BALB/c mice model.

Methods: hUC-MSCs were labelled with GFP-Luc2 protein, followed by characterisation with flow cytometry. Upon intravenous infusion of transduced hUC-MSCs into the healthy BALB/c mice, the cells were dynamically monitored through the bioluminescent imaging (BLI) approach.

Results: Transduction of hUC-MSCs with GFP-Luc2 not only preserved the characteristics of MSCs, but also allowed live monitoring of transduced cells in the mice model. Upon systemic administration, BLI showed that transduced hUC-MSCs first localised predominantly in the lungs of healthy BALB/c mice and mainly remained in the lungs for up to 3 days before eventually cleared from the body. At terminal sacrifice, plasma chemistry biomarkers remained unchanged except for C-peptide levels, which were significantly reduced in the hUC-MSCs group. Histopathological findings further revealed that hUC-MSCs infusion did not cause any adverse effects and toxicity to lung, liver and heart tissues.

Conclusions: Collectively, systemically administrated hUC-MSCs was safe and demonstrated dynamic homing capacity before eventually disappearing from the body.

Citing Articles

Preclinical Evaluation of the Safety, Toxicity and Efficacy of Genetically Modified Wharton's Jelly Mesenchymal Stem/Stromal Cells Expressing the Antimicrobial Peptide SE-33.

Gasanov V, Kashirskikh D, Khotina V, Kuzmina D, Nikitochkina S, Mukhina I Cells. 2025; 14(5).

PMID: 40072070 PMC: 11898551. DOI: 10.3390/cells14050341.


Therapeutic potential of mesenchymal stem cells for fungal infections: mechanisms, applications, and challenges.

Gao Y, Ji Z, Zhao J, Gu J Front Microbiol. 2025; 16:1554917.

PMID: 39949625 PMC: 11821621. DOI: 10.3389/fmicb.2025.1554917.


Rebuilding the myocardial microenvironment to enhance mesenchymal stem cells-mediated regeneration in ischemic heart disease.

Chu Q, Jiang X, Xiao Y Front Bioeng Biotechnol. 2024; 12:1468833.

PMID: 39372432 PMC: 11452912. DOI: 10.3389/fbioe.2024.1468833.

References
1.
Li J, Wu Z, Zhao L, Liu Y, Su Y, Gong X . The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy. Stem Cell Res Ther. 2023; 14(1):381. PMC: 10734083. DOI: 10.1186/s13287-023-03587-y. View

2.
Sarugaser R, Lickorish D, Baksh D, Hosseini M, Davies J . Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells. 2005; 23(2):220-9. DOI: 10.1634/stemcells.2004-0166. View

3.
Teow S, Liew K, Che Mat M, Marzuki M, Aziz N, Chu T . Development of a luciferase/luciferin cell proliferation (XenoLuc) assay for real-time measurements of Gfp-Luc2-modified cells in a co-culture system. BMC Biotechnol. 2019; 19(1):34. PMC: 6570829. DOI: 10.1186/s12896-019-0528-4. View

4.
Liu G, Lv H, An Y, Wei X, Yi X, Yi H . Tracking of transplanted human umbilical cord-derived mesenchymal stem cells labeled with fluorescent probe in a mouse model of acute lung injury. Int J Mol Med. 2018; 41(5):2527-2534. PMC: 5846645. DOI: 10.3892/ijmm.2018.3491. View

5.
Weiss M, Anderson C, Medicetty S, Seshareddy K, Weiss R, VanderWerff I . Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells. 2008; 26(11):2865-74. DOI: 10.1634/stemcells.2007-1028. View